AstraZeneca to Pay $520 Million to Resolve Seroquel Dispute

AstraZeneca has agreed to set aside $520 million as part of a deal with the U.S. attorney’s office in Philadelphia to end investigations related to the sales and marketing practices for its antipsychotic Seroquel, the company says in its third-quarter earnings statement. Pennsylvania is one of several states, including California and Arkansas, that have sued or investigated the company over its alleged off-label promotion of Seroquel (quetiapine fumarate) and Seroquel XR.
Washington Drug Letter